Phase II Study of Pembrolizumab in Combination With Binimetinib and Bevacizumab in Patients With Refractory Colorectal Cancer
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Bevacizumab (Primary) ; Binimetinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 22 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 24 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 22 Jan 2022 Preliminary results presented at the 2022 Gastrointestinal Cancers Symposium.